Novo Nordisk A/S Common Stock (NVO)

Total Liabilities

kr 373.66B

Quarterly · Period ending: · DKK

NVO logo

NVO Total Liabilities

Latest reportedkr 373.66B DKK
NVO Quarterly Total Liabilities · DKK (kr 2.45B → kr 373.66B)
High-resolution chart · PNG

NVO total liabilities history

Quarterly · DKK. Dates are reporting period ends; fiscal years can differ from calendar years.

Novo Nordisk A/S Common Stock Total Liabilities — Quarterly (DKK)
Period endingTotal Liabilities (DKK)
373,664,000,000
356,156,000,000
348,855,000,000
342,392,000,000
314,087,000,000
350,622,000,000
322,309,000,000
276,919,000,000
36,914,863,039
200,010,000,000
207,925,000,000
29,405,667,878
27,880,466,237
24,815,833,035
157,771,000,000
21,891,724,528
20,310,542,852
19,533,158,323
123,762,000,000
16,828,291,329
14,757,238,200
13,099,186,940
13,412,838,004
12,661,809,302
11,462,865,151
10,565,962,827
10,217,665,615
71,955,000,000
64,824,000,000
62,816,000,000
58,930,000,000
54,383,000,000
54,167,000,000
49,320,000,000
52,540,000,000
50,945,000,000
49,389,000,000
53,912,000,000
52,270,000,000
46,013,000,000
45,684,000,000
45,084,000,000
44,830,000,000
42,086,000,000
42,202,000,000
45,349,000,000
36,768,000,000
33,316,000,000
27,020,000,000
29,658,000,000
27,768,000,000
29,009,000,000
28,932,000,000
28,646,000,000
25,037,000,000
30,960,000,000
29,644,000,000
28,852,000,000
27,250,000,000
26,585,000,000
24,562,000,000
24,233,000,000
24,437,000,000
22,898,000,000
23,413,000,000
21,239,000,000
19,008,000,000
17,715,000,000
17,160,000,000
18,860,000,000
17,668,407,600
16,802,145,550
15,440,639,400
16,265,395,250
15,572,130,000
15,256,675,100
14,835,792,450
15,068,646,000
14,567,246,800
15,463,804,290
14,243,744,000
14,263,799,550
14,303,730,620
13,584,789,000
12,087,339,800
10,776,206,250
11,008,546,860
9,916,134,230
9,316,946,210
9,727,603,900
9,194,248,500
8,556,927,210
8,746,648,470
8,855,404,800
12,412,863,790
9,304,501,318
7,511,865,642
5,023,377,873
5,724,886,000
7,996,383,500
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.